Tech Support


This line is for technical support.
For General Enquiries please click General Contact

Cardiovascular Disease

Evaluate compound efficacy with our comprehensive Translational Platform of in vivo cardiovascular disease models


"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

Evaluate Key Aspects of Cardiovascular Disease

Cardiovascular disease is the number one cause of death globally, yet many aspects of CVD are preventable, with millions of people currently being treated for hypertension to reduce cardiovascular risk, and to prevent both heart attack and stroke.

Innovative new therapeutics that can modify or even reverse disease progression are needed to reduce the disease burden in the general population. However, research into the development of novel and improved treatments is complicated by a lack of preclinical hypertensive models.

CrownBio provides highly translatable in vivo models and key technologies for CVD to help progress your novel agents into the clinic.

A Translational Platform of Unique NHP and Rodent Models

Our CardioVascular and Metabolic Disease (CVMD) Translational Technology Platform includes both NHPs and rodent models of CVD.

For rodents, we perform studies across all conventionally available models to suit client needs, as well as in our proprietary, highly translational ZDSD rat model of dysmetabolism and CVD.

We also provide induced disease and advanced study models:

  • Apolipoprotein E-deficient mice
  • Uni-nephrectomized Sprague-Dawley (SD) rats
  • Angiotensin II-induced/elastase-induced abdominal aortic aneurysm mouse models
  • Rabbits fed high-cholesterol diet

Flexible and Customizable Study Design

Our study design is flexible and customizable to offer the best solution for evaluating the in vivo efficacy of your antihypertensive compounds.

Our main CVD study endpoints include:

  • Blood pressure monitoring (including continuous telemetry, tail-cuff)
  • Endothelial dysfunction
  • Hindquarter hyper-perfusion
  • Vascular stiffening (PDW)
  • Cardiac hypertrophy and hyper-dynamics
  • Reduced cardiac reserve
  • Cardiac systolic and diastolic dysfunction
  • Platelet aggregation
  • Blood clotting assays (APTT)